IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

NASDAQ:IBRX • US45256X1037

8.7 USD
+0.09 (+1.05%)
At close: Feb 20, 2026
8.6982 USD
0 (-0.02%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, IBRX scores 3 out of 10 in our fundamental rating. IBRX was compared to 520 industry peers in the Biotechnology industry. IBRX may be in some trouble as it scores bad on both profitability and health. IBRX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IBRX had negative earnings in the past year.
  • IBRX had a negative operating cash flow in the past year.
  • IBRX had negative earnings in each of the past 5 years.
  • IBRX had a negative operating cash flow in each of the past 5 years.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

  • IBRX has a Return On Assets of -67.17%. This is in the lower half of the industry: IBRX underperforms 61.61% of its industry peers.
Industry RankSector Rank
ROA -67.17%
ROE N/A
ROIC N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

  • The Gross Margin of IBRX (99.55%) is better than 99.04% of its industry peers.
  • IBRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IBRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IBRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, IBRX has a worse debt to assets ratio.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -5.83, we must say that IBRX is in the distress zone and has some risk of bankruptcy.
  • IBRX has a worse Altman-Z score (-5.83) than 62.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.83
ROIC/WACCN/A
WACC8.9%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • IBRX has a Current Ratio of 5.77. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
  • IBRX has a Current ratio of 5.77. This is in the better half of the industry: IBRX outperforms 60.46% of its industry peers.
  • IBRX has a Quick Ratio of 5.65. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.65, IBRX is in the better half of the industry, outperforming 60.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.65
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • IBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.87%, which is quite impressive.
  • Looking at the last year, IBRX shows a very strong growth in Revenue. The Revenue has grown by 1025.95%.
  • The Revenue has been growing by 46.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)1025.95%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%425.07%

3.2 Future

  • Based on estimates for the next years, IBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 30.76% on average per year.
  • IBRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 164.62% yearly.
EPS Next Y32.11%
EPS Next 2Y23.22%
EPS Next 3Y24.75%
EPS Next 5Y30.76%
Revenue Next Year651.77%
Revenue Next 2Y278.27%
Revenue Next 3Y229.23%
Revenue Next 5Y164.62%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • IBRX's earnings are expected to grow with 24.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.22%
EPS Next 3Y24.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMUNITYBIO INC

NASDAQ:IBRX (2/20/2026, 8:00:01 PM)

After market: 8.6982 0 (-0.02%)

8.7

+0.09 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-03
Inst Owners14.85%
Inst Owner Change13.42%
Ins Owners3.43%
Ins Owner Change0.62%
Market Cap8.57B
Revenue(TTM)82.56M
Net Income(TTM)-348.62M
Analysts85.45
Price Target12.04 (38.39%)
Short Float %40.85%
Short Ratio4.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.66%
Min EPS beat(2)10.87%
Max EPS beat(2)36.46%
EPS beat(4)3
Avg EPS beat(4)22.08%
Min EPS beat(4)-14.89%
Max EPS beat(4)55.88%
EPS beat(8)4
Avg EPS beat(8)-0.69%
EPS beat(12)6
Avg EPS beat(12)-2.54%
EPS beat(16)7
Avg EPS beat(16)-4.44%
Revenue beat(2)1
Avg Revenue beat(2)6.19%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)13.79%
Revenue beat(4)2
Avg Revenue beat(4)2.05%
Min Revenue beat(4)-5.28%
Max Revenue beat(4)13.79%
Revenue beat(8)5
Avg Revenue beat(8)69.43%
Revenue beat(12)9
Avg Revenue beat(12)193.68%
Revenue beat(16)12
Avg Revenue beat(16)257.51%
PT rev (1m)2.61%
PT rev (3m)15.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.84%
EPS NY rev (1m)0%
EPS NY rev (3m)21.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 103.8
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.08
BVpS-0.53
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.55%
FCFM N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.21%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.65
Altman-Z -5.83
F-Score6
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)249.59%
Cap/Depr(5y)199.51%
Cap/Sales(3y)15458.8%
Cap/Sales(5y)10051.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y32.11%
EPS Next 2Y23.22%
EPS Next 3Y24.75%
EPS Next 5Y30.76%
Revenue 1Y (TTM)1025.95%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%425.07%
Revenue Next Year651.77%
Revenue Next 2Y278.27%
Revenue Next 3Y229.23%
Revenue Next 5Y164.62%
EBIT growth 1Y27.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.58%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNITYBIO INC / IBRX FAQ

Can you provide the ChartMill fundamental rating for IMMUNITYBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IBRX.


What is the valuation status of IMMUNITYBIO INC (IBRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNITYBIO INC (IBRX). This can be considered as Overvalued.


What is the profitability of IBRX stock?

IMMUNITYBIO INC (IBRX) has a profitability rating of 1 / 10.


What is the financial health of IMMUNITYBIO INC (IBRX) stock?

The financial health rating of IMMUNITYBIO INC (IBRX) is 3 / 10.